Title Page

|  |  |
| --- | --- |
| Article Type | Regular Article／Note／Case Report／Others・Enter the type of manuscript you wish to submit. |
| Title in English | Title in English ・Enter the title of manuscript in English. |
| Authors' names in Roman letters (alphabetical characters) | Taro AOBA \*1), Jiro YAKUGAKU2), Hanako SEIRYO1,2), First name LAST NAME3) ・Enter the authors' names in Roman letters (alphabetical characters). At least one author must be designated with an asterisk as the author to whom correspondence should be addressed. |
| Authors' affiliations in English | 1. Department of abc, DEF University,
2. Department of ghi, JKL Pharmacy,
3. Department of mno, PQR Hospital.

・Enter the authors' affiliations in English. |
| Authors' addresses in English | 1. 6-3 Aramaki aza Aoba, Aoba-ku, Sendai, Miyagi 980-8578, Japan
2. 6-3 Aramaki aza Aoba, Aoba-ku, Sendai, Miyagi 980-8578, Japan
3. 6-3 Aramaki aza Aoba, Aoba-ku, Sendai, Miyagi 980-8578, Japan

・Enter the authors' addresses in English. |
| 連絡著者氏名Corresponding author | 青葉 太郎 （Taro AOBA）・連絡著者の姓名を記載してください。（連絡著者が日本人でない場合はアルファベット表記）・Enter the corresponding authors' name. |
| 連絡著者所属および住所 | ◯◯病院薬剤部〒\*\*\*-\*\*\*\*　〇〇県〇〇市〇〇区〇〇1-1・連絡著者の所属と所属先住所を日本語表記で記載してください。・Enter the corresponding authors' affiliations and addresses in Japanese. This is optional for English manuscripts. |
| E-mail | sougo@mail.address.jp ・Enter the corresponding authors' E-mail address. |
| TEL | 012-345-6789  |
| FAX | 012-345-6789  |
| 論文ハイライトHighlights in Japanese | 論文ハイライトは日本語で記載。・和文で200字から500字程度で記載してください。形式は任意です。和文の論文ハイライトは論文発行の際は掲載されません。・Please write highlights in Japanese, approximately 200 to 500 characters. Highlights in Japanese will not be published when the paper is published.  |

（以降は要改ページ）

Main manuscript

|  |  |
| --- | --- |
| Article Type | Regular Article／Note／Case Report／Others・Please enter the same Article Type as in the " Article Type " on the title page. |
| Title in English | Title in English・Please enter the same Title as in the " Title in English " on the title page. |
| Abstract in English | All manuscripts must be accompanied by an abstract in English. The abstract should briefly state the problem or purpose of the research, indicate the theoretical or experimental plan used, summarize the principal findings, and point out the major conclusions.・Abstract should be 250 words or less. |
| Keyword | Drug interactions, Pharmaceutical care, Adherence, molecular target drug・Keyword should be 5 words or less in English. |

**Introduction**

Use Times (English) fonts for the text.

For full instructions, please see the journal’s Submission Guidelines for Authors.

After starting a new line or breaking a line, leave a space and start from the second character.

Each item shall be written in the order of 1.2.3., ..., (1), (2), (3), ....

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Method**

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Case History**

This item will be filled in appropriately. Mainly used for case reports.

Headings such as "Patient Background", "Progress", "Treatment", etc. may be changed or added as appropriate.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Result**

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Discussion**

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Conclusion**

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Acknowledgment**

This item will be filled in appropriately.

**Conflicts of Interest**

Generally, the last paragraph of the manuscript is the place to acknowledge people (dedications), places, funding (you may state grant numbers and sponsors here), and Conflicts of Interest.

**References**

References are placed at the end of the manuscript. Authors are responsible for the accuracy and completeness of all references.

1. 久保田隆廣：アザチオプリン／６-メルカプトプリン代謝に関わる薬物代謝酵素とその遺伝的多型，医薬品相互作用研究，38(3)，1-7，2015．
2. Tanaka A, Takechi K, Watanabe S, Tanaka M, Suemaru K, Araki H: Convulsive liability of cefepime and meropenem in normal and corneal kindled mice. Antimicrob. Agents Chemother., 58(8), 4380-4383, 2014.
3. Ichida K, Matsuo H, Takada T et al.: Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun., 3, 764, 2012.
4. 板垣史郎：第Ⅶ章　血中濃度測定法の概要と測定機器の紹介，TDM実践ハンドブック，唯野貢司・菅原　満・小林道也・齊藤嘉津彦・後藤仁和・戸田貴大編，薬事新報社，東京，pp17-18，2007．
5. Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation, 9th ed, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia PA, 2011.
6. 第十三改訂 調剤指針，日本薬剤師会　編，薬事日報社，東京，2011．
7. 独立行政法人国立健康・栄養研究所：「健康食品」の安全性・有効性情報．https://hfnet.nih.go.jp/　2014年2月9日アクセス．
8. US Food and Drug Administration: Drug Interaction Studies ‒ Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendation.

http://www.solvobiotech.com/documents/FDA\_Draft\_Guidance\_on\_Transporter\_related\_drugdrug\_interactions-2012.pdf　2014年3月1日アクセス．

1. 厚生労働省医政局：医療スタッフの協働・連携によるチーム医療の推進について，医政発0430第1号 (2010年4月30日).

**Figure legends**

Figure legends should not be written in the figure, but should be written in the main text after "References".